A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Facon T et al. Proc ASH 2013;Abstract 2.
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
1Coiffier B et al. Proc ASH 2010;Abstract 114.
Richardson PG et al. Proc ASH 2013;Abstract 535.
Palumbo A et al. Proc ASH 2012;Abstract 446.
Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.
LaCasce A et al. Proc ASH 2014;Abstract 293.
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma 1,2 The Cardiovascular Impact of Carfilzomib in Multiple Myeloma 3 1 Stewart.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.
Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.
Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.
Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously.
ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and the Impact.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
A Phase Ib Dose Escalation Trial of SAR (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
Palumbo A et al. Proc ASH 2014;Abstract 175.
R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Ruan J et al. Proc ASH 2013;Abstract 247.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.
Palumbo A et al. Proc ASH 2012;Abstract 200.
Attal M et al. Proc ASH 2010;Abstract 310.
Korde N et al. Proc ASH 2012;Abstract 732.
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
Oki Y et al. Proc ASH 2013;Abstract 252.
Mateos MV et al. Proc ASH 2013;Abstract 403.
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Coiffier B et al. Proc ASH 2010;Abstract 857.
Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)1 Final Results from.
Forero-Torres A et al. Proc ASH 2011;Abstract 3711.
Zaja F et al. Proc ASH 2010;Abstract 966.
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
Advani RH et al. Proc ASH 2011;Abstract 443.
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Presentation transcript:

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract 685.

Background Current therapies for elderly patients with newly diagnosed multiple myeloma (NDMM) induce about a 30% near- complete response/complete response (nCR/CR) rate, with a discontinuation rate of 35% due to adverse events. Carfilzomib, an irreversible proteasome inhibitor, has significant activity and favorable toxicity in MM. Initial Phase II study results with a combination of carfilzomib with cyclophosphamide and dexamethasone (CCd) showed encouraging activity in elderly patients with NDMM (Proc EHA 2013;Abstract S578). Study objective: To present updated study results on the efficacy and safety of the CCd regimen in patients with symptomatic NDMM who are ≥65 years old or younger patients who are ineligible for autologous stem cell transplantation. Bringhen S et al. Proc ASH 2013;Abstract 685.

Phase II Study Design Bringhen S et al. Proc ASH 2013;Abstract 685. Primary objectives: Safety: Grade 4 neutropenia (>3 d), Grade 4 thrombocytopenia (>7 d), Grade ≥3 nonhematologic toxicity Efficacy: Partial response (PR)

Response (≥nCR) Rate by Treatment Duration Bringhen S et al. Proc ASH 2013;Abstract 685. Median treatment duration: 15 months Median maintenance duration: 9 months Induction phase n = 55 At 1 month4% At 3 months12% At 6 months30% At 9 months47% Maintenance phase n = 43 At 3 months49% At 6 months50% At 9 months56%

Stringent Complete Response (sCR) Rate by Treatment Duration Bringhen S et al. Proc ASH 2013;Abstract 685. Induction phase n = 55 At 4 months2% At 6 months9% At 9 months23% Maintenance phase n = 43 At 3 months24% At 6 months25% At 9 months37%

Progression-Free Survival (PFS) and Overall Survival (OS) Bringhen S et al. Proc ASH 2013;Abstract 685. Clinical variable 2-year PFS rate76% 2-year OS rate87% Long-term outcomes were affected by quality of response: –100% of patients achieving a sCR were alive and in remission at 2 years –74% of patients achieving ≥PR were alive and in remission at 2 years

Adverse Events Summary: Induction Bringhen S et al. Proc ASH 2013;Abstract 685. The more frequent Grade 1 and 2 adverse events were anemia, thrombocytopenia, gastrointestinal toxicity and fatigue or fever. Grade 4 neutropenia occurred in 7% of patients. The more frequent nonhematologic Grade 3 and 4 adverse events were infections and cardiac and gastrointestinal toxicities. Peripheral neuropathy occurred in 9% of patients and was limited in severity to Grades 1 and 2. Patients requiring carfilzomib dose reduction: 21% Patients requiring early discontinuation of treatment due to toxicity: 14%

Adverse Events Summary: Maintenance Bringhen S et al. Proc ASH 2013;Abstract 685. The more frequent Grade 1 and 2 adverse events were anemia, gastrointestinal toxicity and fatigue or fever. Grade 3 and 4 adverse events were rare, recorded in <5% of patients.

Author Conclusions The combination of CCd is effective, with 47% of patients achieving at least a nCR and 23% of patients achieving a sCR. Although a direct comparison between different trials should be viewed with caution, these data compared favorably with the current best standard treatment for elderly patients after diagnosis. The CCd combination is well tolerated and Grade 3 to 4 events were rare. Longer follow-up is needed to better assess long-term outcomes. The carfilzomib dose of 36 mg/m 2 is well tolerated by elderly patients in this setting, and further dose increases could be evaluated in future trials. Bringhen S et al. Proc ASH 2013;Abstract 685.

Investigator Commentary: Phase II Study of CCd for Patients with NDMM Part of the rationale for performing this study was that the rate of discontinuation when treating MM in the elderly is high because of toxicity. So it was of interest to determine whether the CCd regimen could be effective without garnering a high rate of discontinuation. The study focused on patients with NDMM who were elderly or those considered ineligible for stem cell transplant. A high response rate was reported with the CCd combination — 47% nCR or better after the induction phase and 56% after the maintenance phase. The 2-year PFS of 76% and 2-year OS of 87% were also favorable. Patients who achieved a stringent CR had a better OS rate than those who did not, although the difference was not significant. The discontinuation rate was 14%, which is similar to what has been reported with lenalidomide/low-dose dexamethasone but lower than combinations that include melphalan. (Continued)

Overall the regimen was well tolerated. We need to better understand the cardiac and respiratory toxicities associated with this combination. Currently carfilzomib should be used only in the relapsed/refractory setting for MM. These studies are paving the way for this agent to be incorporated into front-line therapy. Interview with Rafael Fonseca, MD, February 14, 2014